-transparent.png){kind=logo}
Buspirone, a new anxiolytic agent, was used in a multiple-baseline, placebo lead-in study for the treatment of aggression and anxiety in six mentally retarded adult patients. The findings demonstrate buspirone's effectiveness in reducing aggression and anxiety in a mentally retarded group of subjects without causing deleterious cognitive side effects. The authors review a body of literature on animal and human subjects where buspirone was used in the treatment of aggression and other mental disorders. Unlike neuroleptics and benzodiazepines, buspirone does not cause sedation which can compromise adaptive and intellectual capacities and thus reduce the patient's potential to benefit from training programs.
J Ratey, and
R Sovner, and
A Parks, and
K Rogentine
January 1992,
International journal of psychiatry in medicine,
J Ratey, and
R Sovner, and
A Parks, and
K Rogentine
December 1996,
Journal of intellectual disability research : JIDR,
J Ratey, and
R Sovner, and
A Parks, and
K Rogentine
January 1992,
The Journal of neuropsychiatry and clinical neurosciences,
J Ratey, and
R Sovner, and
A Parks, and
K Rogentine
November 1971,
American journal of mental deficiency,
J Ratey, and
R Sovner, and
A Parks, and
K Rogentine
December 1979,
Mental retardation,
J Ratey, and
R Sovner, and
A Parks, and
K Rogentine
December 1968,
Journal of mental deficiency research,
J Ratey, and
R Sovner, and
A Parks, and
K Rogentine
September 1994,
International clinical psychopharmacology,
J Ratey, and
R Sovner, and
A Parks, and
K Rogentine
March 1992,
Nursing RSA = Verpleging RSA,
J Ratey, and
R Sovner, and
A Parks, and
K Rogentine
September 1971,
American journal of mental deficiency,
J Ratey, and
R Sovner, and
A Parks, and
K Rogentine
May 1977,
Lancet (London, England),
